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ABSTRACT
Despite significant improvement in treatment of childhood acute myeloid 
leukemia (AML), 30% of patients experience disease recurrence, which is still 
the major cause of treatment failure and death in these patients. To investigate 
molecular mechanisms underlying relapse, we performed whole-exome sequencing 
of diagnosis-relapse pairs and matched remission samples from 4 pediatric AML 
patients without recurrent cytogenetic alterations. Candidate driver mutations were 
selected for targeted deep sequencing at high coverage, suitable to detect small 
subclones (0.12%). BiCEBPa mutation was found to be stable and highly penetrant, 
representing a separate biological and clinical entity, unlike WT1 mutations, which 
were extremely unstable. Among the mutational patterns underlying relapse, we 
detected the acquisition of proliferative advantage by signaling activation (PTPN11 
and FLT3-TKD mutations) and the increased resistance to apoptosis (hyperactivation 
of TYK2). We also found a previously undescribed feature of AML, consisting of a 
hypermutator phenotype caused by SETD2 inactivation. The consequent accumulation 
of new mutations promotes the adaptability of the leukemia, contributing to clonal 
selection. We report a novel ASXL3 mutation characterizing a very small subclone 
(<1%) present at diagnosis and undergoing expansion (60%) at relapse. Taken 
together, these findings provide molecular clues for designing optimal therapeutic 
strategies, in terms of target selection, adequate schedule design and reliable 
response-monitoring techniques.
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INTRODUCTION
Outcome of children with acute myeloid leukemia 
(AML) has improved significantly over the past 30 years 
[1]. Although the majority of patients reach complete 
remission with intensive chemotherapy [2] [3] [4], about 
30% of children with AML experience disease recurrence 
[5] [6]. The outcome of these patients is poor, with a 
probability of overall survival (pOS) ranging between 
29% and 38% [5] [6] [7], making relapsed AML a striking 
challenge and the leading cause of death in these children. 
Given the high frequency of treatment-related deaths (5%–
10%), both with first-line treatment and with protocols 
for relapsed disease, further intensification of standard 
chemotherapy does not seem to be an option for further 
improvement of patientsʼ outcome [8]. This said, better 
knowledge of the molecular lesions underlying AML and 
especially of those involved in the development of relapse 
is mandatory in order to devise novel patient-specific 
treatment strategies. Based on recent studies, disease 
recurrence seems to be associated with clonal evolution 
from early stage to relapse, promoted at least in part 
by chemotherapy itself. This model is supported by the 
seminal work of Ding et al [9] in adult AML, and has only 
recently been confirmed by Farrar et al [10] in childhood 
AML. These authors detected different subclones within 
the whole tumor population which were characterized by 
the acquisition of additional mutations. The unequal fitness 
for survival of various subclones provides them with 
different capability of escaping chemotherapy, this leading 
to relapse. To gain deeper knowledge on the molecular 
mechanisms underlying relapse, we performed whole-
exome sequencing (WES) of primary tumor-relapse pairs 
and matched remission samples from 4 pediatric AML 
patients. Candidate driver somatic events were identified 
and selected for targeted deep sequencing, a sensitive 
assay capable to detect their presence throughout the 
various phases of the disease and to track the dynamics of 
evolution of the various subclones. We focused on cases 
without recurrent cytogenetic alterations, which represent 
about 20% of childhood AML. In this group of patients, 
adequate molecular characterization, risk stratification and 
disease monitoring remain difficult tasks, this leading to a 
great variability in terms of response to therapy and final 
prognosis.
RESULTS
Polyclonal structure and clonal evolution in 
childhood AML revealed by whole-exome 
sequencing
WES of primary tumor-relapse pairs and matched 
remission samples from 4 childhood AML patients (Table 
1) resulted in 9.34x108 reads, yielding >95% diploid 
exome coverage. Average haploid coverage of targeted 
(10X) regions for each sample was between 51X and 
75X. A total amount of 65 single nucleotide variants 
(SNVs) and 17 insertion/deletion mutations (Ins/Dels) 
were considered somatic mutations (for detailed criteria 
refer to Supplementary Information), resulting in: 6 
mutations in AML#1, 41 in AML#2, 11 in AML#3 and 
7 in AML#4. These results agree with the evidence that 
the AML genome usually has a low number of somatic 
mutations [11], with the exception of AML#2 samples, 
which were found to carry a higher burden of mutations, 
despite comparable sequencing performance. Exome-wide 
single-nucleotide polymorphism analysis revealed very 
few copy-number events, concordantly with literature 
reports [11] [12], except in AML#1 sample, which 
carried a large region of gain (17:18965000-81188000) 
and a region of loss (17:0-18965000) of copy number at 
diagnosis. This alteration was lost at relapse, when it was 
no longer detectable within the sensitivity of the assay, 
likely due to its subclonal nature. The list of all novel 
somatic SNVs and Ins/Dels for each patient is provided in 
Supplementary Table S1.1-S1.4 and is summarized in 
Figure 1. WES allowed us to detect diagnosis-specific 
mutations, relapse-specific mutations and mutations 
shared between the primary and the relapse samples of 
each patient. These results confirmed that childhood AML 
is a polyclonal disease, with subclonal architecture of 
the whole leukemic population changing from diagnosis 
to relapse. With the attempt to backtrack the origin of 
such clones, we performed targeted deep sequencing of 
candidate driver mutations based on a comprehensive 
analysis of their recurrence in AML or on a possible 
pathogenetic role, according to literature. We obtained an 
average coverage of ~7000X, with an estimated sensitivity 
of 0.12% in detecting minor subclones. This allowed us to 
infer an estimated clone size based on Mutation Frequency 
(MF), which is the proportion of reads containing the 
mutated allele compared with the total number of reads, 
adjusted for chromosome copy number. Condensed results 
are shown in Table 2.
BiCEBPα mutations are highly persistent 
contrary to WT1 mutations
We detected a highly penetrant biallelic mutation 
of CEBPα (biCEBPα). In patient AML#2, both WES and 
targeted deep sequencing showed a homozygous non-
frameshift insertion (c.937_938insCAG, p.K313delinsQK) 
of CEBPα, involving the bZIP domain, in the majority of 
tumor-cell population, as revealed by MF>80%, both at 
diagnosis and at relapse. Validation by Sanger sequencing 
is shown in Figure 2a. On the contrary, WT1 mutations 
appeared highly unstable. WT1 codes for a transcriptional 
factor recurrently mutated in AML [13], but with a still 
unclear role in leukemia development [14]. The following 
WT1 mutations were found: frameshift insertion 
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Table 1: Clinical features of the AML patients enrolled in this study
Patient 
ID
Gender Age at 
diagnosis 
(years)
FAB 
subtype
WBC at 
diagnosis 
(109/L)
BM blasts 
at diagnosis 
(%)
WBC at 
relapse 
(109/L)
BM blasts 
at relapse 
(%)
Extramedullary 
involvement
Time to 
relapse 
(months)
HSCT
(type)
* AML#1 M 3.3 M2 12.01 70 3.21 60 NO 24 YES 
1 
(AUTO)
AML#2 M 14.5 M5 114.04 92 53.01 80 NO 14 YES 
2 
(MUD)
AML#3 F 7.4 M4 4.02 53 1.7 70 NO 11 YES 
2 
(MUD)
* AML#4 M 12.6 M1 14 80 6.9 24 YES (Tonsils) 18 YES 
2 
(AUTO)
*, patient alive and in CR;1, HSCT in 1st CR;2, HSCT in 2nd CR; HSCT, hematopoietic stem cell transplantation; AUTO, autologous; 
MFD, matched family donor; MUD, matched unrelated donor; WBC, white blood cells.
c.1145_1146insTCGG (p.A382fs) in AML#4 (detected 
only at diagnosis with a MF of 27.6%) and frameshift 
insertion c.1139_1140insTCTTGTAC (p.R380fs) in 
AML#3 [detected both at diagnosis (MF 13.9%) and at 
relapse (MF 4,2%)]. These insertions involve the hotspot 
mutational area of exon 7, associated with AML, resulting 
in loss of the zinc-finger DNA-binding domain of the 
protein [13]. Moreover, SNV c.G962C (p.P1470L) was 
detected only in the relapse sample of AML#2 with a MF 
of 40%, associated with loss of a copy of the wild type 
allele at relapse. The mutation involves exon 5, which is 
not a common site of mutations in AML [13].
Detection of genomic mechanisms underlying 
relapse in AML
Sequencing of primary tumor–relapse pairs allowed 
us identifying specific mutation patterns associated with 
relapse. In patient AML#3, we detected the acquisition 
of an activating mutation (p.A72V) of PTPN11 gained 
at relapse (MF 31.9%). In the same patient, targeted 
deep sequencing revealed a minor subclone carrying 
a FLT3-TKD mutation (p.D835E) already present at 
diagnosis (MF 3.4%), although below the sensitivity of 
WES, and increasing at relapse (MF 13.3%). Given the 
discordant increase of MF of PTPN11 and FLT3-TKD, 
it is reasonable to hypothesize that each characterized a 
different clone.
In patient AML#1, we detected a point mutation 
(c.T2597A, p.L866H) involving the pseudokinase domain 
of TYK2 both in the diagnosis (MF of 43%) and relapsed 
(MF of 14.9%) samples. The pseudokinase domain of this 
protein plays a role in the inhibition of the kinase domain, 
and many cancer-associated mutations described lie in or 
near the interface between these two domains, resulting in 
increased kinase activity in vitro [15] [16]. To the best of 
our knowledge, the mutation we identified has not been 
previously reported, but, considering its involvement of 
the pseudokinase domain, we can speculate it causes an 
increased kinase activity.
In patient AML#2, we detected a frameshift 
insertion (c.6306_6307insCACC, p.P2102fs) of gene 
SETD2 in a considerable fraction of the tumor population 
both at diagnosis (MF 32.5%) and at relapse (MF 31.7%). 
SETD2 is a methyltransferase responsible for H3K36 
trimethylation (H3K36me3), which, in turn, is responsible 
for the recruitment of mismatch repair (MMR) machinery. 
This mutation involves the Set2-Rpb1 interacting (SRI) 
domain at the C-terminal segment, which interacts with 
the phosphor-C-terminal repeat domain (PCTD) of 
elongating RNA polymerase II and leads to the recruitment 
of SETD2 to its target genes [17]. Disruption of this 
domain due to either missense or truncating mutations has 
been previously reported as causing loss of function of the 
methyltransferase activity [18].
Detection of a novel ASXL3 mutation as a late 
event
In patient AML#2, point mutation c.C4409T 
(p.P1470L) of ASXL3 was detected at relapse (MF 
of 29.7%) and backtracked in a very small subclone 
already present in the primary sample (MF of 0.3%). This 
mutation was predicted to be deleterious at protein level. 
Sanger sequencing validation is shown in Figure 2b. This 
represents one of the few examples of ASXL3 mutations 
described in AML [19] [11], as opposed to mutations 
of ASXL1 and ASXL2, the other two members of the 
Additional Sex combs (Asx)-Like family, which appear to 
be quite commonly mutated in AML [19].
DISCUSSION
Given the remarkable frequency of relapse in 
childhood AML and the poor prognosis associated 
with disease recurrence [5] [6], deeper information on 
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Figure 1: Somatic non synonymous mutations detected by WES in 4 pediatric AML. Panel 1a: The image is a plot created 
with the use of Circos software (http://circos.ca/), showing all somatic mutations detected in each patient. Chromosomes are arranged 
clockwise from chromosome 1 to X, each grey circle represents a single patient, proceeding from AML#1 to AML#4 from the outer to the 
inner circle, each dot represents one mutation. Panel 1b: Mutations are grouped into functional categories of genes involved according to 
Pubmed annotation. Each box represents a single mutation, each color represents a distinct patient.
a
b
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Figure 2: Sanger sequencing validation of somatic mutations. Panel 2a: Sanger validation of biCEBPα mutation in patient 
AML#2. Homozygous CAG in-frame insertion is detected in the whole tumor population both at diagnosis and at relapse, while is not 
detected in remission sample used as germinal counterpart. High coverage targeted deep sequencing was actually able to detect a very small 
clone (< 0,1%) carrying this mutation persisting at remission. Panel 2b: Sanger validation of ASXL3 mutation in patient AML#2. Point 
mutation c.C4409T is detected only at relapse. Backtracking of this mutation through high coverage targeted deep sequencing was able to 
detect a minor subclone carrying this mutation even at diagnosis.
Table 2: Results of targeted deep sequencing of candidate driver mutations
Gene Patient Chr Start Ref Alt cDNA Protein MF at 
diagnosis
Inferred 
clone 
size at 
diagnosis*
MF at 
remission
MF at 
relapse
Inferred 
clone 
size at 
relapse*
TYK2 AML#1 19 10467264 A T c.T2597A p.L866H 43,0% 80-90% 0,40% 14,9% 30%
RREB1 AML#2 6 7231420 G A c.G3088A p.V1030M 57,6% 100% ND 53,1% 100%
PSIP1 AML#2 9 15469966 G T c.C1003A p.P335T ND 0% ND 43,9% 40-50%
ASXL3 AML#2 18 31324221 C T c.C4409T p.P1470L 0,3% <1% ND 29,7% 60%
WT1 AML#2 11 32438075 C G c.G962C p.G321A ND 0% ND 40,0% 40%
CEBPA AML#2 19 33792384 - CTG c.937_938insCAG
p.K313 
delinsQK
88,6% 100% 0,08% 80,8% 100%
SETD2 AML#2 3 47098968 - GGTG c.6306_6307 insCACC p.P2102fs 32,5% 60-70% 0,07% 31,7% 60-70%
WISP1 AML#2 8 134239889 G A c.G1040A p.R347K ND 0% ND 34,0% 60-70%
FLT3 AML#3 13 28592640 A T c.T2505A p.D835E 3,4% <10% ND 13,3% 25-30%
WT1 AML#3 11 32417913 - GTACAAGA c.1139_1140 insTCTTGTAC p.R380fs 13,9% 25-30% ND 4,2% <10%
SALL1 AML#3 16 51174616 A G c.T1517C p.I506T ND 0% ND 28,6% 50-60%
UBE2D3 AML#3 4 103722704 T C c.A211G p.T71A ND 0% ND 27,7% 50-60%
PTPN11 AML#3 12 112888199 C T c.C215T p.A72V ND 0% ND 31,9% 60-70%
TEK AML#4 9 27212867 G A c.G2849A p.R950Q ND 0% ND 21,0% 40-50%
WT1 AML#4 11 32417907 - CCGA c.1145_1146 insTCGG p.A382fs 27,6% 55% ND ND 0%
Chr: chromosome; Ref: reference; Alt: alteration; MF: mutation frequency; ND: not detected; *: corrected for copy number 
variations.
a b
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the mechanisms responsible for relapse is desirable to 
improve response to treatment and survival. An important 
point in understanding leukemia genomics is to identify 
leukemia-initiating mutations, i.e. the so called “primary 
events” that result in leukemic transformation. This notion 
will lead us to target the disease at its origin. Despite great 
progress in the last decades, in the majority of cases this 
still remains an unsolved question. However, an equally 
important task is to understand how leukemia evolves once 
this transformation has happened. A better knowledge of 
this process will allow us to refine disease monitoring and 
to choose optimal therapies both in terms of molecular 
targets and schedule.
The term “clonal evolution” refers to tumor 
progression through stepwise acquisition of new 
mutations providing genetic diversity within a cell 
lineage. The dynamics of this process depend on the 
interaction between the specific effect of new mutations 
and micro-environmental conditions, such as resource 
limitations and chemotherapy. This results in selection and 
expansion of more fit subclones, together with eradication 
or self-extinction of less fit subclones [20]. Our results, 
graphically plotted in Figure 1, clearly show clonal 
evolution from diagnosis to relapse, further confirming 
the very recent findings of Farrar et al [10]. In fact, while 
the genetic alterations shared between the primary-tumor 
and the relapse samples prove a common origin from an 
ancestral clone, the evidence of diagnosis-specific and 
relapse-specific mutations strongly supports a branching 
model of clonal progression. “Primary events” responsible 
for the origin of AML are highly penetrant in the tumor 
population and stable during the course of disease, that 
is continuously present in one patient’s leukemia from 
diagnosis to relapse. On the other end of the spectrum, 
“secondary events” occur later and only in a fraction of 
cells, conferring a greater amount of complexity to the 
genomic profile of the disease [21]. In order to clarify 
if clones giving rise to relapse were already present at 
diagnosis but below the threshold of detection of WES, or 
they arose later in the course of the disease, we performed 
targeted deep sequencing of putative driver mutations. 
Interestingly, targeted deep sequencing was also able to 
detect persistence of some leukemia-related mutations 
(biCEBPα, TYK2 and SETD2) during relapse at a very 
low MF (0.08%, 0.4% and 0.07% respectively), further 
supporting the potential application of Next Generation 
Sequencing techniques in minimal residual disease 
monitoring [22] [23] [24]. On the contrary, the great 
instability of WT1 mutations, both in terms of loss and 
acquisition, concordant with previous reports [10] [13] 
[25] [26], suggests caution in adopting WT1 monitoring-
based techniques. According to the model described above, 
biCEBPα mutation, defined as disruption of both CEBPα 
alleles [27], was detected in the vast majority of the tumor-
cell population of one of our patients, both at diagnosis 
and at relapse. This finding mirrors the pathogenetic role 
of the event: CEBPα, in fact, appears to play multiple roles 
in normal hematopoiesis, both in regulating differentiation 
and cell proliferation, and its disruption alone results in 
the accumulation of blasts [28]. Thus, the stability of 
biCEBPα supports its role in defining a distinct molecular 
and clinical subtype of AML [29], as reported in the 2016 
WHO classification [30].
The aim of our work was to uncover mutational 
patterns underlying relapse. The first pattern we report 
is related to an increased proliferation signal giving 
significant advantage to a specific clone. This model 
is well depicted in Figure 3a, tracing the dynamics 
of clonal evolution in patient AML#3. A small FLT3-
TKD-mutated subclone (<10%) of the primary leukemia 
survived chemotherapy and underwent expansion at 
relapse (25-30%). An additional clone, characterized by 
the acquisition of a PTPN11 mutation, appeared later, but 
overcame other clones becoming the predominant one at 
relapse (60-70%). It is well known that both these kinds of 
events lead to increased cell proliferation and/or survival 
[31] [32]. Not only the interaction of the mutation effect 
with the environment, but also the mutual competition 
of various subclones and the proliferative kinetics of 
each one within the tumor, turn out to be fundamentals 
of clonal evolution. Although these late events may not 
be necessary for leukemogenesis per se, they clearly play 
an important role in disease progression by conferring 
a specific proliferative advantage. This is particularly 
relevant considering that these mutations could potentially 
be the target for tailored therapy. Moreover, FLT3/
TKD and ITD being subclonal mutations is one of the 
plausible explanations of unsatisfying results of FLT3 
inhibitors, along with many others concerning inadequate 
in vivo inhibition of the target, development of secondary 
pharmacokinetic or pharmacodynamic resistance, and 
influence of FLT3-mutant allelic burden. Hence, accurate 
molecular characterization of the disease also at relapse 
can guide the choice of optimal therapies, even targeting 
the various subclones within the bulk tumor by using 
multiple agents simultaneously.
A fitness advantage can also be expressed as an 
abnormal resistance to apoptosis causing clonal survival 
to therapy. This feature was found in patient AML#1, 
where a clone carrying a deleterious point mutation of 
TYK2, a member of the janus tyrosine kinases (JAK) 
family, contributed to relapse. These cytoplasmic kinases 
mediate intracellular activation of a variety of pathways 
affecting cellular growth, differentiation and survival 
[33]. Hyperactivation of TYK2 pathway, either through 
mutations or other mechanisms, has been shown to 
contribute to aberrant cell survival through upregulation 
of the anti-apoptotic protein BCL2 in several T-ALL-cell 
lines [34]. There is also growing evidence for a role of 
the anti-apoptotic members of BCL2 family in promoting 
therapy resistance and survival both in AML and 
myelodysplastic syndromes [35] [36] [37]. In the same 
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way, a TYK2-activating mutation likely promoted clonal 
survival to therapy in our patient. This clone represented 
about a third of the whole blast population at relapse; thus, 
unknown events must have promoted survival of other 
clones. Nonetheless, a single relapse sample is a one-shot 
picture where, as described above, the relative proportion 
of various clones is strongly related to the kinetics of 
dividing cells. In the long run instead, persistence of a 
reservoir of cells ‘throughout’ therapy can also be related 
to a more stable or even quiescent state.
A third and unexpected pattern underlying clonal 
evolution is the acquisition of a mutator phenotype 
Figure 3: Graphical representation of clonal evolution from primary diagnosis to relapse based on targeted deep 
sequencing of driver mutations. Panel 3a: Clonal evolution in patient AML#3. The primary tumor differentiates into subclones 
through the acquisition of new somatic mutations, including WT1 and FLT3-TKD. Those clones survive chemotherapy and contribute 
to relapse. Later acquisition of additional mutations, such as PTPN11, SALL1 and UBE2D3, further increases clonal heterogeneity and 
confers a higher degree of complexity to the disease. Reported percentages refer to the estimated size population of each clone inferred 
from the MF calculated on targeted deep sequencing data for each mutation and adjusted for CN. Panel 3b: Clonal evolution in patient 
AML#2. The entire tumor population both in the primary and in the relapse samples carries a biCEBPα and a RREB1 mutation. The 
inactivation of SETD2 in a substantial fraction of the cells is associated with the acquisition of a mutator phenotype causing differentiation 
into multiple minor subclones through the acquisition of additional somatic mutations, increasing the plasticity and adaptability of the 
leukemia. High coverage targeted deep sequencing was able to detect persistence of biCEBPAα and SETD2 mutation during remission. 
Reported percentages refer to the estimated size population of each clone inferred from the MF calculated on targeted deep sequencing data 
for each mutation and adjusted for CN.
a
b
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marked by accumulation of a large number of mostly 
subclonal mutations due to failure of DNA repair. This 
has already been described in cases of relapsed ALL [38] 
[39], while is a surprisingly new feature in AML, which is 
traditionally known as characterized by a very low number 
of somatic mutations and absence of genomic instability 
[11]. Indeed, in patient AML#2, both in the diagnosis 
and the relapse samples, we detected a much higher 
burden of mutations than in the other three analyzed. This 
mutator phenotype is associated with a SETD2 truncating 
mutation, able to disrupt its function in the recruitment 
of the MMR machinery [40]. Besides being found in 
clear cell renal carcinoma [41] [42], SETD2 mutations 
have recently been identified by Zhu et al [18] in 6.2% 
out of 241 patients with acute leukemia (both AML and 
ALL). SETD2 mutations have also been described as 
gained during relapse in childhood ALL [43]. Our results 
further support the idea of a role of SETD2 mutations in 
AML, particularly contributing to clonal selection and 
survival. In fact, the accumulation of additional mutations, 
dramatically increasing the plasticity and adaptability of 
the leukemia cells, leads in the end to a higher chance 
of escaping therapy. A graphical representation of clonal 
evolution in patient AML#2 from diagnosis to relapse 
shown in Figure 3b.
Finally, we also identified a novel point mutation of 
ASXL3. It was detected in a very small subclone (<1%) 
in the primary sample, but underwent expansion (60%) 
at relapse. While mutations of the other two members of 
Additional Sex combs (Asx)-Like family, ASXL1 and 
ASXL2, are recurrently mutated in AML, mutations of 
ASXL3 have been described only twice in the setting 
of AML so far [11] [19]. Moreover, while ASXL1 
mutations, according to their role in modulating gene 
expression through epigenetic regulation, are regarded as 
“landscaping” events early initiating leukemogenesis at 
a pre-leukemic stage [44] [45], the ASXL3 mutation we 
identified appears to be a late event.
In summary, we ultimately uncovered the polyclonal 
structure of pediatric AML, revealing a global shifting 
in the mutational spectrum from diagnosis to relapse. 
Our results further confirm the recent evidence [10] 
of clonal evolution in childhood AML and highlight a 
remarkable and previously unknown genomic complexity 
of the disease. Possible patterns of clonal evolution are 
various and heterogenous in each single patient, further 
supporting the need for individualized diagnostic and 
therapeutic strategies. Moreover, monitoring the dominant 
clone detected at diagnosis may not be a reliable marker 
of impending relapse, while the detection and track of 
emerging subclones may be more informative. With great 
technological improvements of sequencing platforms in 
the last and future years, both in terms of time needed 
to perform the analysis and costs, we may predict that 
a similar approach will soon be available to clinical 
use. These results provide greater knowledge of the 
clonal architecture underlying relapse. More in depth, 
considering the different types of genes involved, we 
proved the idea [46] that once the leukemic transformation 
has occurred, clonal evolution results from a complex 
interplay of ‘driver’ lesions, such as mutations providing 
a proliferative advantage (i.e. FLT3 or PTPN11 activating 
mutations) or an increased survival (i.e TYK2 mutations), 
as well as ‘deleterious’ lesions, causing self-extinction, 
and ‘passenger’ lesions. We also found a ‘mutator’ lesion 
(i.e. SETD2 inactivation) as a previously undescribed way 
of increasing the rate of other genetic changes therefore 
promoting the perpetuating of the disease.
MATERIALS AND METHODS
Patient samples
Patient samples analyzed were collected at the 
time of diagnosis, first complete remission and relapse, 
respectively, from 4 children with de novo AML 
other than promyelocytic leukemia, enrolled in the 
Associazione Italiana Ematologia Oncologia Pediatrica 
(AIEOP) 2002/01 Study [3] after obtaining written 
informed consent from the parents according to the 
Declaration of Helsinki. FAB morphological diagnosis 
and immunophenotypic analysis was centrally reviewed at 
the laboratory of Pediatric Haematology of the University 
Hospital in Padova. Chromosome analysis was performed 
on bone marrow (BM) aspirates using standard laboratory 
procedures. Karyotypes were reported according to 
the International System for Human Cytogenetic 
Nomenclature (ISCN 2005). For fluorescence in-situ 
hybridization (FISH), an MLL locus specific (LSI) dual 
colour probe for 11q23 (Abbott-Vysis, Downers Grove, 
IL) was employed. Clinical features of the patients are 
reported in Table 1.
Whole-exome sequencing and bioinformatics 
analyses
Total DNA was extracted from BM leukemia/
mononucleated cells of the 4 AML patients by QIAamp 
DNA Mini kit (Qiagen) and exome library preparation 
was performed by Nextera Rapid Capture Enrichement 
kit (Illumina, San Diego, CA) according to the 
manufacturer’s recommendations. Bridge amplification 
was conducted through cBot cluster amplification system/
TruSeq PE Cluster Kit v3-cBot-HS (Illumina). Sequencing 
by synthesis was performed on HiScanSQ sequencer 
(Illumina) at 100 bp in paired-end mode. After adapter 
and quality trimming, implemented by AdapterRemoval 
algorithm [47], reads were aligned with Burrows-Wheeler 
Aligner [48] to the reference human genome hg19/
Oncotarget56754www.impactjournals.com/oncotarget
GRCh37. Genome Analysis Toolkit (GATK) (Haplotype 
Caller) and MuTect packages were used to detect Ins/Dels 
and SNVs respectively from exome-seq data [49] [50]. 
Variants present in dbSNP database (http://www.ncbi.nlm.
nih.gov/project/SNP), 138 edition, and in 1000 Genomes 
database (http://wwww.1000genomes.org), February 
2012 edition with frequency greater than 1% were 
excluded. Synonym SNVs were excluded, thus resulting 
in evaluating only non-synonymous SNVs, nonsense 
SNVs, SNVs at splicing sites and Ins/Dels, both frameshift 
and non-frameshift. In further analysis, only high-quality 
somatic mutations were considered, according to their 
absence in the control sample obtained at time of complete 
remission from the corresponding patient (for detailed 
criteria refer to Supplementary Information). The effect 
of mutations at the protein level was predicted with the 
computational tools SIFT and PROVEAN [51]. Copy 
number alterations were detected by Control-FREEC 
Software [52] on WES data, comparing primary and 
relapse samples to remission sample of corresponding 
patient.
Targeted deep sequencing of candidate driver 
mutations on MiSeq
In order to clarify molecular mechanisms 
underlying disease relapse, among mutations detected 
by WES, we further selected candidate driver mutations 
for targeted deep sequencing, based on a comprehensive 
analysis of their recurrence in AML or on a possible 
pathogenetic role, according to literature. DNA library 
preparation was performed with Nextera XT DNA Prep 
kit (Illumina). Amplicons of the corresponding regions 
were prepared through PCR reaction with AmpliTaq 
FastStart kit (Applied Biosystem). The full list of 
primers used at this stage is reported in Supplementary 
Table S2. Deep sequencing was performed on MiSeq 
System (Illumina) according to the manufacturer’s 
recommendations. The complete output of targeted deep 
sequencing is reported in Supplementary Table S3. For 
a detailed description of output data analysis refer to 
Supplementary Information.
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